WallStreetZenWallStreetZen

NASDAQ: QNTM
Quantum Biopharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their QNTM stock forecasts and price targets.

Forecast return on equity

Is QNTM forecast to generate an efficient return?

Company
-19.44%
Industry
27.3%
Market
56.1%
QNTM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is QNTM forecast to generate an efficient return on assets?

Company
-7.49%
Industry
12.36%
QNTM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

QNTM earnings per share forecast

What is QNTM's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.54

QNTM revenue forecast

What is QNTM's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$8.7M
Avg 2 year Forecast
$15.0M

QNTM vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
QNTM$35.00N/AN/A
BGM$13.07N/AN/A
UPC$3.93N/AN/A
CRDL$1.24$9.00+625.81%Buy
IRWD$0.70$4.94+603.70%Hold
View Top Pharmaceutical Stocks

Quantum Biopharma Stock Forecast FAQ

What is QNTM's earnings growth forecast for 2025-2025?

(NASDAQ: QNTM) Quantum Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 139.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.27%.

Quantum Biopharma's earnings in 2025 is -$15,238,008.

In 2025, QNTM is forecast to generate -$4,175,071 in earnings, with the lowest earnings forecast at -$4,175,071 and the highest earnings forecast at -$4,175,071.

If you're new to stock investing, here's how to buy Quantum Biopharma stock.

What is QNTM's revenue growth forecast for 2025-2026?

(NASDAQ: QNTM) Quantum Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 0.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 53.77%.

Quantum Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast QNTM's revenue for 2025 to be $23,532,218, with the lowest QNTM revenue forecast at $23,532,218, and the highest QNTM revenue forecast at $23,532,218.

In 2026, QNTM is forecast to generate $40,530,721 in revenue, with the lowest revenue forecast at $40,530,721 and the highest revenue forecast at $40,530,721.

What is QNTM's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: QNTM) forecast ROA is -7.49%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.36%.

What is QNTM's Earnings Per Share (EPS) forecast for 2025-2025?

(NASDAQ: QNTM) Quantum Biopharma's current Earnings Per Share (EPS) is -$11.07. In 2025, QNTM's EPS is forecast to hit -$1.54 (min: -$1.54, max: -$1.54).

What is QNTM's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: QNTM) forecast ROE is -19.44%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.